Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections by Crump, John A et al.
Epidemiology, Clinical Presentation, Laboratory Diagnosis,
Antimicrobial Resistance, and Antimicrobial Management of Invasive
Salmonella Infections
John A. Crump,a,b Maria Sjölund-Karlsson,b Melita A. Gordon,c,d Christopher M. Parrye,f,g
Centre for International Health, University of Otago, Dunedin, Otago, New Zealanda; Division of Foodborne, Waterborne, and Environmental Diseases, National Center for
Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USAb; Department of Clinical Infection, Microbiology and
Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdomc; Malawi-Liverpool-Wellcome Trust Clinical Research
Programme, Blantyre, Malawid; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japane; Department of Clinical Research, London School of
Hygiene and Tropical Medicine, London, United Kingdomf; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdomg
SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .902
INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .902
EPIDEMIOLOGY AND CLINICAL ASPECTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .902
Typhoidal Salmonella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .902
Burden of disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .902
Sources and modes of transmission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .902
Host risk and protective factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .902
Presenting symptoms and signs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .904
Patient outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .905
(i) Complications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .905
(ii) Relapse and reinfection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .905
(iii) Fecal shedding and chronic carriage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .905
Prevention and control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .906
Nontyphoidal Salmonella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .906
Burden of disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .906
Sources and modes of transmission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .906
Host risk and protective factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .907
Presenting symptoms and signs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .908
Patient outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .908
Prevention and control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .908
Challenge of Distinguishing Invasive Salmonella Infections from Other Febrile Conditions in Areas of Endemicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .908
LABORATORY DIAGNOSIS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .909
Bacterial Culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .909
Serologic Assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .911
Antibody detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .911
Rapid serologic tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .911
Molecular Assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .912
Other Diagnostic Tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .912
New Diagnostic Approaches . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .912
Other Laboratory Findings In Enteric Fever. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .913
ANTIMICROBIAL RESISTANCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .913
Development of Antimicrobial Resistance among Typhoidal Salmonella Strains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .913
Development of Antimicrobial Resistance among Nontyphoidal Salmonella Strains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .914
Molecular Mechanisms of Resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .915
Multiple-drug resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .915
Fluoroquinolone resistance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .915
Cephalosporin resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .915
Macrolide resistance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .916
(continued)
Published 15 July 2015
Citation Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. 15 July 2015.
Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance,
and antimicrobial management of invasive Salmonella infections.
Clin Microbiol Rev doi:10.1128/CMR.00002-15.
Address correspondence to John A. Crump, john.crump@otago.ac.nz.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/CMR.00002-15
crossmark
October 2015 Volume 28 Number 4 cmr.asm.org 901Clinical Microbiology Reviews
 o
n
 January 18, 2016 by guest
http://cm
r.asm
.org/
D
ow
nloaded from
 
ANTIMICROBIAL MANAGEMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .916
Traditional First-Line Antimicrobials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .916
Fluoroquinolones. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .916
Extended-Spectrum Cephalosporins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .917
Azithromycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .917
Carbapenems and Tigecycline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .918
Antimicrobial Combinations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .918
Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .918
Treatment of Severe Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .918
Treatment of Chronic Carriage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .918
Evidence Needs for Antimicrobial Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .918
CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .919
ACKNOWLEDGMENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .919
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .919
AUTHOR BIOS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .936
SUMMARY
Salmonella enterica infections are common causes of bloodstream
infection in low-resource areas, where they may be difficult to
distinguish from other febrile illnesses andmay be associated with
a high case fatality ratio. Microbiologic culture of blood or bone
marrow remains themainstay of laboratory diagnosis. Antimicro-
bial resistance has emerged in Salmonella enterica, initially to the
traditional first-line drugs chloramphenicol, ampicillin, and trim-
ethoprim-sulfamethoxazole. Decreased fluoroquinolone suscep-
tibility and then fluoroquinolone resistance have developed in
association with chromosomal mutations in the quinolone resis-
tance-determining region of genes encoding DNA gyrase and to-
poisomerase IV and also by plasmid-mediated resistance mecha-
nisms. Resistance to extended-spectrum cephalosporins has
occurred more often in nontyphoidal than in typhoidal Salmo-
nella strains. Azithromycin is effective for the management of un-
complicated typhoid fever and may serve as an alternative oral
drug in areas where fluoroquinolone resistance is common. In
2013, CLSI lowered the ciprofloxacin susceptibility breakpoints
to account for accumulating clinical, microbiologic, and pharma-
cokinetic-pharmacodynamic data suggesting that revision was
needed for contemporary invasive Salmonella infections. Newly
established CLSI guidelines for azithromycin and Salmonella en-
terica serovar Typhi were published in CLSI document M100 in
2015.
INTRODUCTION
Salmonella enterica is a leading cause of community-acquiredbloodstream infections in many low- and middle-income
countries (1, 2). Salmonella enterica serovars Typhi, Paratyphi A,
Paratyphi B, and Paratyphi C may be referred to collectively as
typhoidal Salmonella, whereas other serovars are grouped as non-
typhoidal Salmonella (NTS). Typhoidal Salmonella strains are hu-
man host-restricted organisms that cause typhoid fever and para-
typhoid fever, together referred to as enteric fever. NTS strains
may be host generalists, infecting or colonizing a broad range of
vertebrate animals, or may be adapted or restricted to particular
nonhuman animal species (3).
We review invasive Salmonella infections with respect to epi-
demiology, clinical presentation, laboratory diagnosis, antimicro-
bial resistance, and antimicrobial management. In particular, we
focus on the development of antimicrobial resistance and recent
changes to the interpretation of antimicrobial susceptibility tests
for fluoroquinolones and to establishment of methods and inter-
pretive criteria for azithromycin.
EPIDEMIOLOGY AND CLINICAL ASPECTS
Typhoidal Salmonella
Burden of disease. In 2000, typhoid fever was estimated to cause
approximately 21.7million illnesses and 216,000 deaths and para-
typhoid fever 5.4 million illnesses (4). Typhoid and paratyphoid
fevers were included in the Global Burden of Disease 2010 (GBD
2010) project, when they were together estimated to account for
12.2 million disability-adjusted life years (5) and 190,200 deaths
(6). Children in south-central and southeast Asia are at particular
risk (4). The International Vaccine Institute estimated that there
were 11.9 million typhoid fever illnesses and 129,000 deaths in
low- and middle-income countries in 2010 (Fig. 1) (7). Typhoid
fever appears to have become more common in sub-Saharan Af-
rican countries (8) or to have been underappreciated there in the
past (9). In some Asian countries, Salmonella serovar Paratyphi A
has accounted for a growing proportion of enteric fever (10, 11).
Sources and modes of transmission. Typhoidal Salmonella is
transmitted predominantly through water or food contaminated
with human feces. The risk for infection is high in low- and mid-
dle-income countries where typhoidal Salmonella is endemic and
that have poor sanitation and lack of access to safe food and water
(4). Enteric fever in high-income countries is usually acquired
abroad and is associated with travel to areas of endemicity (12),
although clusters may be associated with food preparers who are
chronic carriers of Salmonella serovar Typhi (13).
Host risk and protective factors. A range of host risk and pro-
tective factors have been identified for typhoidal Salmonella infec-
tion. Salmonella enterica is acid susceptible and must survive the
gastric acid barrier to successfully establish infection in the termi-
nal ileum. Gastric acid secretion has been shown to be suppressed
during acute enteric fever, subsequently returning to normal and
with the degree of acid suppression relating to the infection sever-
ity (14, 15). The acid tolerance of the organismmay be an impor-
tant determinant of transition to the small intestine and can vary
with the infecting serovar (16).
Past infection withHelicobacter pylori has been suggested to be
associated with typhoid fever, perhaps because both diseases are
associated with reduced gastric acidity. In a case-control study in
India, the presence of serum anti-H. pylori immunoglobulin G
antibodies was associated with typhoid fever with an adjusted
Crump et al.
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odds ratio (OR) of 2.03 (95% confidence interval [CI], 1.02 to
4.01) (17). In this study, illiteracy, being part of a nuclear family,
nonuse of soap, and consumption of ice cream were also associ-
ated with an increased risk of typhoid. H. pylori IgG antibodies
develop 1 to 3 months after acute infection and so could indicate
either active or previous infection. In a similar case-control study
done in Jakarta, Indonesia, with an age-stratified analysis, the level
of H. pylori IgG but not IgA antibody was higher in typhoid fever
patients than in community controls (18). Furthermore, plasma
gastrin levels, indicative of hypochlorhydria, were not signifi-
cantly elevated in typhoid fever cases compared to controls. In a
multivariable analysis, there was an association of H. pylori IgG
seropositivity with typhoid fever with an odds ratio of 1.93 (95%
CI, 1.10 to 3.40). However, the authors suggested that the associ-
ation may result from common environmental exposure to poor
hygiene rather than implying a causal relationship through re-
duced gastric acid secretion.
A limited number of studies have demonstrated host genetic
factors that influence susceptibility to enteric fever. The cystic fi-
brosis transmembrane conductance regulator (CFTR) is a protein
expressed on the gastric mucosa. In vitro experiments have shown
that the wild-type protein facilitates adherence and entry of Sal-
monella serovar Typhi, but not Salmonella serovar Typhimurium,
into intestinal epithelial cells (19). This binding and entry are me-
diated by an interaction between Salmonella serovar Typhi lipo-
polysaccharide (LPS) and type IVb pilus and CFTR protein resi-
dues (20, 21). Expression of CFTR on the intestinal epithelium is
stimulated by the presence of Salmonella serovar Typhi and com-
mensal bacteria in the intestine (22, 23).Mutations in CFTR, such
as F508del, are associated with cystic fibrosis. In the presence of
this mutation there is no uptake of Salmonella serovar Typhi into
intestinal epithelial cells, and in heterozygotes uptake into cells is
reduced (19). Thus, the F508del mutant may provide protection
against infection following exposure to Salmonella serovar Typhi.
A case-control study in Jakarta, Indonesia, of mutations in the
CFTR allele and enteric fever found no participants with the
F508delmutation. It is possible that variations inCFTRother than
F508del may provide protection against enteric fever. Amicrosat-
ellite polymorphism in intron 8, IVS8CA, of the CFTR gene was
associated with protection from enteric fever (P 0.003) (24). In
a further analysis of additional regions, the presence of one or
more protein-expressing variations, including the IVS8 TG11TG12
genotype, provided a modest protection from enteric fever (OR,
0.57; P 0.01) (25).
Immune defense against enteric fever is likely to depend in part
at least on cellular immunity. A study in Vietnam showed associ-
ations between major histocompatibility complex (MHC) class II
and class III genes and enteric fever (26). Alleles of HLA-DR,
HLA-DQ, and the proinflammatory gene TNFA were associated
with either resistance or susceptibility to enteric fever among hos-
pitalized patients. Circulating levels of both tumor necrosis factor
alpha (TNF-) and soluble TNF receptor have been reported to be
elevated in enteric fever and higher in severe disease (27, 28). The
capacity to secrete TNF- following ex vivo stimulation has been
shown to be reduced in the acute phase of typhoid fever, with the
degree correlating with severity of disease and delayed recovery
(28, 29). The association with susceptibility to enteric fever and
the polymorphism in the tumor necrosis factor alpha gene
(TNFA-308) could not be replicated in an Indonesian population
with community-diagnosed enteric fever, and there were no asso-
ciations with polymorphisms in a number of other proinflamma-
tory genes (30). A possible explanation for the discrepancy in the
results is that the association of TNFA polymorphisms is with
disease severity rather than susceptibility to infection. Of interest,
HLA-DR haplotypes were associated with protection from severe
enteric fever among Indonesian patients, although this could not
be linked with TNF- production capacity (31). Further analysis
of the Vietnamese population again suggested that a haplotype in
theTNF region gives protection against enteric fever, but the caus-
ative disease locus remains to be determined (32). In a recent
genome-wide association study of patients in Vietnam and Nepal
with blood culture-confirmed enteric fever, a strong association
FIG 1 Typhoid incidence in low-income and middle-income countries (risk adjusted and corrected for blood culture sensitivity). (Reprinted from reference 7
with permission from Elsevier.)
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was found for HLA-DRB1 as a major contributor to resistance
against enteric fever, presumably through antigen presentation
(33).
Toll-like receptors (TLRs) mediate the innate immune re-
sponses to bacterial pathogens. TLR5 binds to bacterial flagellin
and TLR4 to LPS. Among Vietnamese patients with enteric fever
there were no significant associations with the TLR5392STOP poly-
morphisms (34). There were also no associations with TLR4 poly-
morphism. However, because of low gene frequencies, the sample
may have been inadequate to give a definitive answer (35). In the
mouse model of typhoid fever, control of Salmonella serovar Ty-
phimurium infection is dependent on the natural resistance-asso-
ciated macrophage protein 1 (Nramp1), but in Vietnamese pa-
tients with enteric fever, there was no allelic association between
the NRAMP1 alleles and typhoid fever susceptibility (36). Poly-
morphisms in thePARK2/PACRG gene cluster, linked to ubiquiti-
nation, and proteasome-mediated protein degradation previously
found to be associated with susceptibility to infection withMyco-
bacterium leprae were weakly associated with susceptibility to en-
teric fever in an Indonesian population (37).
The relationship between HIV infection and enteric fever has
not been studied in detail. In the early 1990s, Peruvian patients
with HIV infection were reported to be at increased risk of Salmo-
nella serovar Typhi disease (38). Subsequent reports in Africa and
Asia highlighted the association of nontyphoidal Salmonella sero-
vars, rather than Salmonella serovar Typhi, with HIV (1, 3). In a
study of unselected hospitalized adults with fever in Tanzania,
HIV appeared to be protective against Salmonella serovar Typhi
infection (odds ratio, 0.12; 95% CI, 0.03 to 0.49; P 0.001) (39).
The 26 positive Salmonella serovar Typhi cultureswere taken from
24 (9.8%) of 244 HIV-uninfected patients and two (1.2%) of 161
HIV-infected patients. A similar inverse association between ty-
phoid and HIV infection was noted in a meta-analysis of blood-
stream infection studies from Africa (1). The use of hospitalized
patients may be a source of bias, and the relationship requires
further study.
Presenting symptoms and signs. In areas of endemicity, pa-
tients admitted to hospital are usually school-aged children or
young adults between 5 and 25 years of age, and both sexes are
affected equally (40–42). Many patients do not require admission
to hospital, due to either mild disease, self-medication, or being
treated in health stations, clinics, or as hospital outpatients (43–
45). These community-managed cases may be of nonspecific ill-
ness that is not recognized clinically as enteric fever, especially
among children under 5 years of age (46–48).
After ingestion of Salmonella serovar Typhi or Paratyphi A, an
asymptomatic period follows that usually lasts 7 to 14 days (range,
3 to 60 days). Human challengemodels, both in the 1950s to 1970s
(49) and more recently (50), contributed to the understanding of
incubation and very early symptoms in typhoid fever. These stud-
ies have shown that a higher infecting dose is associated with a
higher attack rate and a shorter interval to bacteremia but has no
influence on the time to symptom development or disease sever-
ity. Recent human challenge studies have also demonstrated that a
proportion of patients develop a subclinical or asymptomatic bac-
teremia and that fecal shedding can occur in the period before
symptom development, during primary infection (51). As symp-
tomatic disease develops, the predominant symptom is the fever
(40–42, 52). The temperature rises gradually during the first week
of the illness and reaches a high plateau of 39 to 40°C the following
week. There is little diurnal variation, although the patternmay be
modified by anti-pyretic medications. Patients can have influenza-
like symptoms, a dull frontal headache, malaise, anorexia, a dry
cough, sore throat, and occasionally epistaxis. Constipation is a
frequent early symptom although many patients will experience
diarrhea at some point. Enteric fever can present as a diarrheal
illness and occasionally with bloody diarrhea. Most patients have
abdominal pain that is diffuse and poorly localized. Nausea is
common, and vomiting occurs in more severe cases. It is unusual
for a patient hospitalized with typhoid to have no abdominal
symptoms and normal bowel movements. Rigors are uncommon
and this can be a useful feature to distinguish the illness from
malaria (53).
Besides fever, physical examination findings may be few. A
slightly distended abdomen with a “doughy” consistency and dif-
fuse tenderness is common. Occasionally the pain and tenderness
is intense in the right iliac fossa, mimicking appendicitis, or may
be more generalized, raising the possibility of peritonitis. Moder-
ate soft and tender hepatomegaly and splenomegaly eventually
develop in most patients. A relative bradycardia is described as
being common in enteric fever, although some reports suggest
that a tachycardia is more common and that a relative bradycar-
dia, when present, is not specific for enteric fever (54–57). Rose
spots, a blanching erythematous maculopapular rash with lesions
approximately 2 to 4 mm in diameter, have been reported in 1 to
30% of cases (Fig. 2) (41, 58). They usually occur on the abdomen
and chest and more rarely on the back, arms, and legs. Rose spots
are easilymissed in dark-skinnedpatients. Abnormal lung sounds,
especially scattered wheezes, are common and can suggest pneu-
monia, but if the chest radiograph is normal and fever high,
enteric fever should be considered. There may be a history of
intermittent confusion, and many patients have a characteristic
apathetic affect. Important differences in children, compared to
adults, are a greater frequency of diarrhea and vomiting, jaundice,
febrile convulsions, nephritis, or typhoid meningitis (59–62). En-
teric fever may also complicate pregnancy and rarely cause neo-
natal infection (63, 64).
If the disease is untreated, by the second to fourth week pa-
tients may become increasingly sick with weight loss, weakness,
FIG 2 Rose spots on the abdomen of a patient with typhoid fever. (Reprinted
from reference 603.)
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and an altered mental state, and complications develop (40–42).
Complications occur in 10 to 15% of hospitalized patients and are
particularly likely in patients who have been ill for more than 2
weeks. Many complications have been described (Table 1), of
which gastrointestinal bleeding, intestinal perforation, and ty-
phoid encephalopathy are most closely associated with risk for
death (65–67). Other complications of enteric fever include psy-
chiatric disturbance and pneumonia. Paratyphoid fever has been
described as a less severe infection than typhoid fever. However,
recent studies suggest that Salmonella serovar Paratyphi A, an in-
creasing problem in many areas in Asia (10, 11), can cause a dis-
ease with severity equal to that of Salmonella serovar Typhi (68).
Patient outcomes. (i) Complications. Gastrointestinal bleed-
ing resulting from the erosion of a necrotic ileal Peyer’s patch
through the wall of an enteric vessel may develop in up to 10% of
hospitalized patients (41, 69, 70). Bleeding is usually slight and
self-limited, resolving without the need for blood transfusion.
However, in some cases bleeding is substantial, and it can be rap-
idly fatal when a large vessel is involved. Evidence for silent gas-
trointestinal bleeding may be sudden collapse of the patient or a
steadily falling hematocrit.
Intestinal perforation, usually involving the ileum but occa-
sionally involving the colon, is a serious complication of enteric
fever (41, 69–74). This may occur in 1 to 3% of hospitalized pa-
tients (41, 70, 75) and be manifest by an acute abdomen or more
insidiously by worsening abdominal pain, a rising pulse, and fall-
ing blood pressure in an already-sick patient. Severely ill patients
often display restlessness, hypotension, and tachycardia. A chest
radiograph may show free gas under the diaphragm. Abdominal
ultrasound is useful for demonstrating and aspirating feculent
fluid in the peritoneal cavity.
Studies from Indonesia and Papua New Guinea have revealed
an important subgroup of patients with a high case fatality ratio
associated with mental confusion or shock (systolic blood pres-
sure of90mmHg in adults or80mmHg in children) andwith
evidence of decreased skin, cerebral, or renal perfusion (76–78).
Themental state of the patientmay range from apathetic although
rousable to severely agitated, delirious, or obtunded. Complete
stupor or coma is infrequent. Patients with advanced illness may
display the “typhoid facies,” described as a thin, flushed face with
a staring, apathetic expression. Mental apathy may progress to an
agitated delirium, frequently accompanied by hand tremor, trem-
ulous speech, and gait ataxia. If the patient’s condition deterio-
rates further, the features described in the writings of Louis and
Osler may occur, including muttering delirium, twitching of the
fingers and wrists, agitated plucking at the bedclothes, and a star-
ing and unrousable stupor, also known as coma vigil (40).
A wide range of other complications has been described. The
most common include cholecystitis, hepatitis, pneumonia, acute
kidney injury, and myocarditis (69, 70). Typhoid fever during
pregnancy may be complicated by miscarriage but appears to be
mitigated by antimicrobial treatment (63). Mother-to-child
transmission may lead to neonatal typhoid, a rare but severe and
life-threatening illness (64, 79).Meningitis occurs among children
below 1 year of age (62).
In the preantimicrobial era, enteric fever carried a case fatality
ratio of approximately 10 to 30% (40, 41, 80). With effective an-
timicrobials, the case fatality ratio is usually less than 1%. Re-
ported case fatality ratios have varied from less than 2% in Paki-
stan (59) and Vietnam (66, 70) to 30 to 50% in some areas of
Indonesia (76, 77) and Papua New Guinea (78). Severe and fatal
disease has been associated with both male and female sex, ex-
tremes of age, and antimicrobial drug resistance (59, 65, 67, 70, 73,
81). The most important contributor to a poor outcome is prob-
ably a delay in instituting effective antimicrobial treatment.
(ii) Relapse and reinfection. Typhoid fever relapse is manifest
by a second episode of fever, often but not always milder than the
first, occurring 1 week to 3 weeks after the recovery from the first
episode (52). Relapse may occur in as many as 5 to 10% of un-
treated or chloramphenicol-treated typhoid patients. Typically re-
lapsing patients have an isolate with an antimicrobial susceptibil-
ity pattern identical to that during the first episode and can be
managed with the same drug (82, 83). Reinfection has also been
described and is distinguished by differences in the susceptibility
pattern, Vi phage type, or molecular type of isolates (82–84).
(iii) Fecal shedding and chronic carriage. Most patients with
acute enteric fever continue to excrete Salmonella serovar Typhi or
Paratyphi A in their stool or urine for some days after starting
antimicrobial treatment, and up to 10% may do so for up to 3
months. Approximately 1 to 4%of patients still excrete the organ-
ism at 3 months and are unlikely to cease shedding. Those excret-
ing at 1 year meet the formal definition of “chronic carrier.”
Among carriers detected by screening, one-quarter give no history
of acute typhoid fever. Fecal carriage is more frequent among
individuals with gallbladder disease and is most common among
women over 40 years of age. In the Far East there is an association
between fecal carriage and opisthorchiasis, and urinary carriage is
associated with schistosomiasis and nephrolithiasis. Most chronic
carriers have no symptoms, although acute typhoid fever has
been reported among carriers on occasions. Chronic carriage can
occur with both Salmonella serovar Typhi and Paratyphi A (85).
Chronic Salmonella serovar Typhi carriers have an increased risk
of carcinomaof the gallbladder (86, 87). In one of the few attempts
to measure the prevalence of Salmonella serovar Typhi carriage in
a population, in Santiago, Chile, in 1980, there were estimated to
be 694 chronic carriers per 100,000 population (88).
The detection of chronic carriers depends on the labor-inten-
sive isolation of the bacteria from stool or urine. Excretion can be
TABLE 1 Complications of enteric fever
Complication
Gastrointestinal bleeding
Intestinal perforation (usually of terminal ileum, occasionally of colon)
Encephalopathy accompanied by hemodynamic shock
Hepatitis
Cholecystitis
Pneumonia (may be due to secondary infection with other organisms such
as Streptococcus pneumoniae)
Myocarditis
Acute kidney injury, nephritis
Deep-seated abscess (e.g., spleen, large joint, bone)
Anemia
Meningitis (in infants)
Neurological disturbance (cerebellar ataxia)
Miscarriage
Psychiatric disturbance
Disseminated intravascular coagulation
Relapse
Chronic carriage (fecal or urinary carriage for1 yr)
Carcinoma of gallbladder
Invasive Salmonella Infections
October 2015 Volume 28 Number 4 cmr.asm.org 905Clinical Microbiology Reviews
 o
n
 January 18, 2016 by guest
http://cm
r.asm
.org/
D
ow
nloaded from
 
intermittent, and at least three negative stool cultures are required
for patients to be considered free of infection (89). Identification
of carriers of Salmonella serovar Typhi can be accomplished by
serial stool culture. The detection of IgG to theVi antigen has been
proposed as a method to detect chronic carriers, and the test has
proved valuable in the context of outbreak investigations (90–93).
Its role in detecting carriers in the general population of areas of
endemicity where background levels of IgG to Vi may be high, or
where the Vi vaccine is widely used, is less clear (94). Nucleic acid
amplification tests of gallbladder contents may be a diagnostic
addition in the future (95).
Prevention and control. Enteric fever in Western Europe and
North America declined in parallel with the introduction of treat-
ment of municipal water, pasteurization of dairy products, and
exclusion of human feces from food production (96). More re-
cently declines have occurred in Latin America (4) and in some
Asian countries (97) in parallel with economic transition and wa-
ter and sanitation improvements. Strategies for enteric fever pre-
vention include improving sanitation, ensuring the safety of food
and water supplies, identification and treatment of chronic carri-
ers of Salmonella serovar Typhi, and the use of typhoid vaccines to
reduce the susceptibility of hosts to infection or disease. Reducing
the proportion of people without access to safe drinking water is a
component of Millenium Development Goal 7 (98).
Two typhoid vaccines are currently available in the United
States. The Ty21a vaccine is a live, attenuated, oral vaccine con-
taining the chemically attenuated Salmonella serovar Typhi strain
Ty21a, and the parenteral Vi vaccine is based on the Salmonella
serovar Typhi Vi capsular polysaccharide antigen. Ty21a is avail-
able as orally administered enteric capsules and is licensed in the
United States for use in children6 years of age and elsewhere for
children as young as 2 years of age. The Vi-based vaccine is li-
censed in theUnited States for children aged2 years. The cumu-
lative protective efficacy over 3 years has been estimated to be 48%
for Ty21a and 55% for Vi polysaccharide vaccine in a Cochrane
systematic review (99). The effectiveness of the parenteral Vi vac-
cine has recently been confirmed in young children, and the pro-
tection of unvaccinated neighbors of Vi vaccinees has been dem-
onstrated (100). The earliest Vi conjugate vaccine to reach clinical
trials, Vi-rEPA, has been shown to be safe and immunogenic in
Vietnamese children aged 2 to 5 years, providing protective effi-
cacy of 91.5% (101) and an estimated 89% cumulative efficacy
after 3.8 years (99). Phase 2 studies of other Vi conjugate vaccines
have been completed (102). A number of Vi conjugate constructs
are now in development.However, Vi-basedmonovalent vaccines
do not offer protection against most paratyphoid fever, because
only Salmonella serovars Typhi, Paratyphi C, andDublin carry the
Vi antigen. Salmonella serovar Typhi Ty21a does not express the
Vi antigen, and clinical field trials suggest that while Ty21a may
provide limited protection against Salmonella serovar Paratyphi
B, it does not offer cross-protection against Salmonella serovar
Paratyphi A (103, 104). The development of effective vaccines for
paratyphoid fever is an important priority.
Nontyphoidal Salmonella
Burden of disease. In industrialized countries, nontyphoidal Sal-
monella is transmitted predominantly by commercially produced
food contaminated by animal feces, and it usually causes a self-
limited enterocolitis with diarrhea in humans. Bloodstream
infection occurs in approximately 6% of patients with diarrheal
enterocolitis; infants, young children, the elderly, and the immu-
nocompromised are at particular risk for bacteremia (105–108).
Nontyphoidal Salmonella serovars are diverse in their host range
and epidemiology and vary in their propensity to cause blood-
stream infection and severe human disease. Salmonella serovar
Typhimurium is considered to be a typical host generalist with a
broad host range and modest likelihood of causing invasive dis-
ease, while other nontyphoidal Salmonella serovars such as Salmo-
nella serovars Heidelberg, Dublin, and Choleraesuis are markedly
more likely than Salmonella serovar Typhimurium to cause hos-
pitalization, invasive disease, or death. Some serovars, such as Sal-
monella serovar Newport, are associated with a lower case fatality
ratio (0.3%) than Salmonella serovar Typhimurium (108, 109).
The reasons for differences in host specificity among Salmonella
serovars are complex and incompletely understood. Genome deg-
radation appears to be associated with host specificity in Salmo-
nella Typhi and Salmonella Paratyphi A, which have absent and
deactivated genes compared with Salmonella Typhimurium. In
addition, typhoidal Salmonella serovars elicit a dampened im-
mune response compared with nontyphoidal Salmonella serovars
associated with diarrhea and also produce a unique exotoxin,
which may explain differences in the clinical phenotype (110,
111).
Modes of nontyphoidal Salmonella transmission in low- and
middle-income countries are less well understood than in indus-
trialized countries. Malaria and malnutrition predispose to inva-
sive disease among children, and HIV does so among both chil-
dren and young adults (3). Worldwide in 2006, enteric NTS was
estimated to cause 93.8 million diarrheal illnesses and 155,000
deaths (112). In the Institute for Health Metrics and Evaluation
Global Burden of Disease 2010 project, enteric nontyphoidal Sal-
monella was estimated to account for 4.8 million disability-ad-
justed life years (5) and 81,300 deaths (6). In 2010, nontyphoidal
Salmonella was estimated to cause approximately 3.4 million in-
vasive infections and 681,000 deaths; 57% of these illnesses and
deaths occurred in Africa (113).
The most widely reported serovars associated with invasive
disease across Africa are Salmonella serovar Typhimurium and
Salmonella serovar Enteritidis (114–123). Some serovars are
prominent in localized areas, such as Salmonella serovar Concord
in Ethiopia (124), Salmonella serovar Bovismorbificans inMalawi
(125), Salmonella serovar Stanleyville and Salmonella serovar
Dublin in Mali (126), and Salmonella serovar Isangi in South Af-
rica (127), the last being associated with a nosocomial outbreak.
Anovel Salmonella serovar Typhimuriummultilocus sequence
type, ST313, has been described and currently accounts for much
invasive disease in sub-Saharan Africa. This sequence type has a
unique prophage repertoire and a degraded genome that shows
some convergence with that of Salmonella serovar Typhi, raising
the possibility of increased host specialization or invasiveness
(128). One putative virulence gene, ST313td, has been described
in Salmonella serovar Typhimurium ST313 and also found in
other human invasive and enteric pathovars, notably Salmonella
serovar Dublin (129). However, to date no other candidate viru-
lence genes have been associated with invasive nontyphoidal Sal-
monella strains from HIV-infected patients (130). Ongoing
genomic and phenotypic investigations of Salmonella serovar Ty-
phimurium ST313 from Africa may be an area promising further
new insights.
Sources andmodes of transmission.While sources andmodes
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of transmission of enteric nontyphoidal Salmonella have been
studied extensively in industrialized countries (131), epidemio-
logic studies of nontyphoidal Salmonella infections in areas of
endemicity in sub-Saharan Africa are very limited (132). In indus-
trialized countries, animal products and, increasingly, produce
contaminated with animal feces are important sources of nonty-
phoidal Salmonella (131). Contact with animals, such as reptiles,
and with animal environments are important sources of nonty-
phoidal Salmonella infection not associated with food (133). Al-
though transmission by food contaminated with animal feces
must be considered, greater roles than in industrialized countries
for waterborne transmission, transmission directly from animals
and their environments, and transmission between people, inde-
pendent of a nonhuman animal reservoir, have been hypothe-
sized. Partial genome molecular studies of nontyphoidal Salmo-
nella strains from invasive human infections and those carried by
animals among the households of childrenwith invasive disease in
Africa have so far failed to find similarities between strains, while
family members of index cases have been found to have more
closely related isolates (134, 135). Although it was hypothesized
that the degraded genome of Salmonella serovar Typhimurium
ST313might reflect a reduced host range and human restriction of
the sequence type, recent studies have indicated that ST313 also
displays a severe invasive phenotype in chickens but reduced po-
tential for cecal colonization (136). The emergence of two distinct
clades of Salmonella serovar Typhimurium ST313 across Africa
shows temporal relationships to acquired antimicrobial resistance
determinants, particularly to the first-line antimicrobial chloram-
phenicol, and to the emergence of HIV on the continent (137).
This suggests that transmission among humans may have exerted
genomic selection pressure. Little is known about the epidemiol-
ogy or phenotype of prevalent enteric nontyphoidal Salmonella
strains in Africa. Nontyphoidal Salmonella was not a common
cause of moderate to severe diarrheal disease in African sites par-
ticipating in the Global Enterics Multicenter Study (138). How-
ever, asymptomatic carriage of nontyphoidal Salmonella appears
to be relatively common (134, 138). The contribution to asymp-
tomatic carriage or diarrheal disease in Africa of Salmonella sero-
var Typhimurium ST313 is still unclear, although the diversity of
nontyphoidal Salmonella strains from enteric samples is likely to
be wide (139).
Host risk and protective factors. Previous gastric surgery, per-
nicious anemia, andmedications that reduce the acid barrier, such
as antacids, H2 antagonists, and proton pump inhibitors, increase
susceptibility to nontyphoidal Salmonella enteric infection (140–
144). Individuals at the extremes of age are at increased risk of
invasive nontyphoidal Salmonella. In the case of older people, this
may be because of multiple comorbidities, including diabetes, re-
nal disease, or medications. The recent use of antimicrobials is
associated with increased risk of multidrug-resistant Salmonella
infection (145).
In Africa, there is a clear bimodal age distribution that con-
trasts with the continuous age distribution through childhood to
adulthood of typhoid fever. Children aged from 6 to 18 months
and adults aged 25 to 40 years, in whom HIV prevalence is also
highest, show the highest incidences of invasive nontyphoidal Sal-
monella in Africa (146). Among children, there is a relatively low
incidence of invasive nontyphoidal Salmonella below the age of 6
months. Thismay be attributable to protection afforded by breast-
feeding, by lack of exposure to contaminatedwater or food during
exclusive breastfeeding, or by transplacental transfer of protective
IgG (147). However, neonatal invasive nontyphoidal Salmonella
does occur, particularly among children born outside a health care
facility (148, 149).
Unlike enteric fever, for which where there are no clear clinical
associations with classic immunocompromising conditions, inva-
sive nontyphoidal Salmonella is associated with many forms of
immunocompromise (150). These include disorders of oxidative
cellular killing, such as chronic granulomatous disease, in which
nontyphoidal Salmonella is described as the most common cause
of bloodstream infection and the third leading cause of all infec-
tions (151). Children who are homozygous for sickle cell disease
are susceptible to invasive nontyphoidal Salmonella infections
(152). In addition, inherited deficiencies of cytokines that are
known to be critical for intracellular killing, particularly interleu-
kin-12 (IL-12) and IL-23, are associated with invasive nontyphoi-
dal Salmonella (153).
There is an overwhelming association of invasive nontyphoidal
Salmonellawith advancedHIVdisease amongAfrican adults, with
95% of cases being HIV infected (1, 122, 150, 154–157). Among
children, HIV is a risk factor (OR, 3.2) for infection with NTS
(158). In cohorts of African children with invasive nontyphoidal
Salmonella, around 20% are typically HIV infected (116). Several
immune defects have been described that could contribute to the
apparent exquisite susceptibility of adults with advanced HIV to
recurrent invasive nontyphoidal Salmonella. These include the
loss of IL-17-producing CD4 cells in the gut mucosa, permitting
rapid invasion (159), and dysregulated excess production of anti-
LPS IgG that inhibits serum killing of extracellular Salmonella in a
concentration-dependent fashion (160, 161). Nontyphoidal Sal-
monella establishes an intracellular niche during invasive disease
in HIV infection (162). It is likely that this is facilitated by the
ability of the bacteria to be rapidly internalized before serum kill-
ing can occur (163). Once in the intracellular niche, reduction and
dysregulation of proinflammatory cytokine responses in HIV-in-
fected individuals, observed in vivo (162, 164) and ex vivo (165),
allow intracellular survival and persistence, leading to frequent
recrudescence and relapses of bacteremia with identical strains of
nontyphoidal Salmonella (154, 166). In contrast with HIV-in-
fected adults, a lack of protective antibody appears to be impli-
cated in the susceptibility of African children18 months of age
to invasive nontyphoidal Salmonella disease, and antibody is likely
to be important both for cellular and cell-free control of nonty-
phoidal Salmonella disease in children (147, 167, 168).
An association of invasive nontyphoidal Salmonella with ma-
laria amongAfrican childrenwas first noted in 1987 inWest Africa
(117). Since then, recentmalaria (116), acute severemalaria (169),
and severe malarial anemia, but not cerebral malaria (170), have
all been specifically described as risk factors for invasive nonty-
phoidal Salmonella. The co-relationship of malaria with invasive
nontyphoidal Salmonella among children has also been described
both spatially, contrasting high- and low-incidence areas for ma-
laria (171, 172), and temporally, with both rising (172) and falling
(173, 174) background incidences of malaria being associated
with corresponding changes in the incidence of invasive nonty-
phoidal Salmonella. However, this association is not necessarily
specific for invasive nontyphoidal Salmonella, and a strong asso-
ciation of malaria with all bacteremias has been noted in Kenyan
children, where the bacteremia incidence rate ratio associated
with malaria parasitemia is 6.69 (175). A causal relationship with
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malaria was inferred by a reduced odds ratio for sickle cell trait,
which is protective against malaria, among children with bactere-
mia, particularly due to Gram-negative organisms (175).
Malnutrition is also associated with invasive nontyphoidal Sal-
monella in African children (116, 176). In rural Kenya, nontyphoi-
dal Salmonella bacteremia was associated with childmalnutrition,
with an odds ratio (95% confidence interval) of 1.68 (1.15 to 2.44)
(158). Invasive nontyphoidal Salmonella disease is strongly sea-
sonal among both adults and children, coinciding with the rainy
season (114). It is not clear whether this reflects waterborne trans-
mission, seasonal malaria transmission during periods of in-
creased rainfall, associated food scarcity and malnutrition, or a
combination of these factors.
Presenting symptoms and signs. The clinical presentation of
invasive nontyphoidal Salmonella infection is nonspecific among
both children and adults. Therefore, recognition and manage-
ment are challenging, particularly in settings without facilities for
the laboratory diagnosis of bloodstream infection. Invasive non-
typhoidal Salmonella presents as a febrile illness. Respiratory
symptoms are frequently present, and diarrhea is often not a
prominent feature. However, often the clinician is faced with a
febrile patient without an obvious clinical focus of infection. Fea-
tures on physical examination include abnormal respiratory find-
ings, such as rapid respiratory rate or chest crepitations suggestive
of pneumonia, and hepatosplenomegaly in 30 to 45% of cases
(116, 154, 177, 178). Splenomegaly has been shown to be a useful
clinical feature to predict nontyphoidal Salmonella bacteremia
among adults in areas where HIV seroprevalence is high (179).
The lack of current or recent diarrhea in invasive nontyphoidal
Salmonella infection among immunosuppressed patients has been
well described in many settings (180, 181). Patients with invasive
nontyphoidal Salmonella also often display the features of under-
lying conditions such as anemia,malnutrition, and advancedHIV
disease. It has been widely recognized that the nonspecific presen-
tation among children often fulfills empirical algorithms for lower
respiratory tract infection. In such circumstances, health care
workers may commence antimicrobial treatment that is inappro-
priate for invasive nontyphoidal Salmonella, especially when an-
timicrobial resistance among Salmonella enterica is common (182,
183). In addition, febrile presentations are often not identified as
bloodstream infection by pediatric guidelines (184, 185), resulting
in delayed or missed antimicrobial treatment.
Patient outcomes. Nontyphoidal Salmonella meningitis may
occur among children. It has poor outcomes and a high case fatal-
ity ratio (186). Although lower respiratory tract infection-related
symptoms and signs are common in invasive nontyphoidal Sal-
monella infection, these are frequently caused by other pathogens
(154). Lobar pneumonia caused by nontyphoidal Salmonella has
been described in a child (187).
Recurrent invasive nontyphoidal Salmonella infection was
quickly recognized as a defining feature of AIDS in the 1980s.
Recurrence typically occurs in 20 to 30% of treated adults with
HIV, usually within 4 to 6 months (154, 162). Partial- and whole-
genome sequencing has been used to establish that 80%of cases of
recurrence are due to recrudescence with an identical strain, likely
arising from intracellular persistence and latency. Only 20% of
recurrences represent reinfection with a new strain (154, 166).
Patients with HIV infection, once established on effective antiret-
roviral treatment after an episode of invasive nontyphoidal Sal-
monella, appear to be less likely to experience recurrence (188). In
areas whereHIV seroprevalence is not high, persistent nontyphoi-
dal Salmonella bacteremia may suggest mycotic aneurysm. Non-
typhoidal Salmonella intravascular, bone, and joint infections are
frequently reported in industrialized countries (189).
Mortality from invasive nontyphoidal Salmonella infection is
high in all subgroups, even if appropriate antimicrobial therapy is
given. Case fatality ratios among HIV-infected adults from Afri-
can case series were50% early in theHIV epidemic (122, 154). A
study from Thailand reported a case fatality ratio of 36% among
all cases of invasive nontyphoidal Salmonella but 59% among
cases whowereHIV infected (190). The reported case fatality ratio
among adults appears to have fallen gradually in Africa, after ini-
tial reports in the 1980s and 1990s, to around 20 to 25% more
recently. This has been attributed largely to improved recognition
and more prompt and effective management (191). It is possible
but not certain that more-effective antimicrobials, such as fluoro-
quinolones replacing chloramphenicol, may also have contrib-
uted to these improving outcomes (114). More recently, with the
wide availability of HIV care and treatment services, including
antiretroviral therapy, across Africa, there are reports of a reduced
incidence of andmortality from invasive nontyphoidal Salmonella
and other bloodstream infections among adults (192). The case
fatality ratio among cohorts of children with invasive nontyphoi-
dal Salmonella disease across Africa has been reported to be 20 to
28% and highest among children2 years of age. This is compa-
rable to the case fatality ratio associated with other bloodstream
infections (116, 158, 177).
Prevention and control. Food safety from farm to fork is fun-
damental to the control of nontyphoidal Salmonella in industrial-
ized countries. The very limited evidence base on sources and
modes of transmission of nontyphoidal Salmonella in low- and
middle-income countries hampers the development of evidence-
based prevention advice. However, some host risk factors for in-
vasive nontyphoidal Salmonella disease are modifiable, and inter-
ventions to prevent these mitigate disease risk. Efforts to prevent
and effectively manage malaria are likely to be important in this
regard. Indeed, the prevalence of invasive nontyphoidal Salmo-
nella has declined in parallel with that of malaria in a number of
areas (173–175). HIV care and treatment services, including the
use of trimethoprim-sulfamethoxazole prophylaxis to prevent op-
portunistic infections (193, 194) and antiretroviral therapy to re-
verse immunosuppression, are likely to reduce the risk for inva-
sion by nontyphoidal Salmonella and in turn disease incidence
(188, 195).
Despite invasive nontyphoidal Salmonella being overlooked in
evaluations of disease burden to date (5, 6, 196), some vaccine
development efforts are under way (197). However, despite their
availability for livestock and poultry, there are currently no non-
typhoidal Salmonella vaccines available for humans. The occur-
rence of invasive nontyphoidal Salmonella disease predominantly
among immunocompromised persons challenges vaccine devel-
opment (160, 198).
Challenge of Distinguishing Invasive Salmonella Infections
from Other Febrile Conditions in Areas of Endemicity
In settings where enteric fever and invasive salmonellosis are en-
demic, most patients with fever self-treat by visiting a local phar-
macy or shop selling antimicrobials. Those who do not respond to
self-treatment may then present to a health center, outpatient
clinic, or hospital. Many other viral, bacterial, and protozoal in-
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fections resemble enteric fever and invasive salmonellosis (9). En-
teric fever and invasive nontyphoidal salmonellosis should always
be considered when suspected malaria has not been confirmed or
the illness has not responded to antimalarial therapy. In areas of
endemicity, rickettsial infections, leptospirosis, brucellosis, and
dengue should be considered in the differential diagnosis. Nonin-
fectious conditions characterized by fever, including lymphopro-
liferative disorders and vasculitides, should not be overlooked.
Clinical judgment can be unreliable, and broad-spectrum an-
timicrobials may be needed in the initial management of se-
verely ill febrile patients. A few clinical algorithms have been
developed for febrile disease diagnosis (199–202), but these are
limited by a lack of accuracy.
LABORATORY DIAGNOSIS
Diagnostic tests are needed for the diagnosis of invasive Salmo-
nella infections, for the detection of convalescent and chronic fecal
carriage of typhoidal Salmonella, and to estimate the burden of
disease for public health assessment. Different tests and biological
samples may be required for each situation (203). It may be im-
portant to be able to detect both Salmonella serovar Typhi and
Salmonella serovar Paratyphi A infections, as they cannot be dis-
tinguished from each other clinically. Microbial culture is the
mainstay of diagnosis. Antibody and antigen detection and nu-
cleic acid amplification tests have limitations, as described below.
Bacterial Culture
The definitive diagnosis of enteric fever relies on the isolation of
Salmonella enterica from normally sterile clinical samples, usually
blood and bonemarrow. Culture confirms the diagnosis and pro-
vides an isolate for antimicrobial susceptibility testing, epidemio-
logic typing, and molecular characterization. In untreated pa-
tients with enteric fever, the blood culture is positive in 80% of
patients or more (41, 204, 205). In areas of endemicity where
antimicrobials are frequently taken before evaluation, the yield
from blood culture can be as low as 40%, and in this setting, bone
marrow aspirate culture is usually considered the reference stan-
dard method, with a sensitivity of 80%. The importance of the
volume of blood taken for blood culture relates to the number of
bacteria in the blood (211). Invariably, the number of viable bac-
teria in each milliliter of blood is less than 10, and frequently it is
only one or less (162, 206–210). The optimum period for detect-
ing organisms circulating in the bloodstream is considered to be in
the first or second week of the illness, although cultures can still
remain positive in the third week in the absence of antimicrobial
exposure (41, 204, 207). Quantitative bacteriology studies have
shown declining counts with an increasing duration of disease
(210). Various methods are used to improve the yield of blood
culture (summarized in Table 2), but all remain limited by the low
numbers of viable bacteria in blood.
A number of studies have demonstrated a higher sensitivity
from bonemarrow culture aspirate than from blood culture, even
after antimicrobials have been taken for several days and regard-
less of the duration of disease prior to sampling (162, 215, 228–
233) (Table 3). The increased sensitivity of bone marrow culture
compared with blood culture relates to the higher bacterial con-
centration in bone marrow (234). Bone marrow culture is more
frequently positive in patients with severe and complicated disease
(226). A bonemarrow aspiration is an uncomfortable and special-
ized procedure, uncommonly performed outside research studies,
although some authors have suggested that a fine-needle tech-
nique can be well tolerated (235). It is notable that most studies
demonstrating a higher yield from bone marrow were performed
TABLE 2 Modifications of blood culture methods to improve detection of Salmonella Typhi and Salmonella Paratyphi A
Methodological issue Methoda Advantages References
Formulation of broth
blood culture
medium
Bile salt broth/Oxgall Bile salts and Oxgall inhibit bactericidal activity of blood,
improve detection of Salmonella Typhi and Salmonella
Paratyphi A, unsuitable for isolation of non-enteric
fever pathogens
212–215, 219
Supplementation of BHI broth or TSB with 0.05% SPS SPS inhibits bactericidal activity of blood 213, 214, 220
Soybean casein digest broth (Bactec system) Automated detection, quality-assured medium, expense,
complete system includes automated culture
instrument
216–218
Peptone-enriched TSB supplemented with BHI solids
(BactAlert)
Inclusion of charcoal or resins in the medium to
adsorb anticobials
Charcoal or resins in the medium should adsorb
antimicrobials
216, 218
Blood-to-broth dilution ratio: at least 1:10 is
important, although higher dilutions may be
beneficial
Reduce bactericidal activity of blood and dilute
antimicrobials present
221
Sample used Clot culture: blood clot, after separation from serum,
added to preprepared streptokinase broth
Removal of serum thought to reduce bactericidal activity
of blood, improved yield even when on
chloramphenicol treatment
213, 221–225
Lysis of cells in blood before start of culture May release intracellular bacteria 226, 227
Centrifugation of blood followed by direct culture on
solid medium
May concentrate low numbers of bacteria and produce
the bacteria growing on the plate more quickly
226, 227
Duration of
incubation
Prolonging duration of blood culture incubation Incubation duration of longer than 7 days increased yield
in older blood cultures systems; modern continuously
monitored automated systems usually positive within
48 h
204, 220
a BHI, brain heart infusion; TSB, tryptic soy broth; SPS, sodium polyethanol sulfonate.
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before modern blood culture media and continuously monitored
blood culture instruments were available and generally used low
volumes of blood for culture (232, 233). It is possible that if a
sufficiently large volume of blood is taken for culture using mod-
ern media and systems (211), blood culture may be as sensitive as
bone marrow culture. Rose spot culture has been reported to be
positive in 70% of patients, although in practice rose spots are
rarely present (228). Cerebrospinal fluid culture is usually positive
only in very young children (62).
Salmonella enterica may be isolated from feces in up to 30% of
patients with typhoid fever and in1% of urine samples, with the
number of organisms recoverable from feces increasing through-
out an untreated illness (41). The sensitivity of fecal culture in-
creases from about 10% in a single sample to about 30%by testing
multiple samples. Sensitivity is also improved by usingwhole feces
rather than rectal swabs and by using a Selenite F enrichment step
and selective media. Culture of bile obtained from an overnight
duodenal string capsule provides a sensitivity similar to that for
blood culture and offers an additional means to isolate typhoidal
Salmonella from patients or carriers. Young children and those
with severe disease may be unable to tolerate the procedure (215,
230, 236). A positive culture from feces, duodenal contents, or
urine requires cautious interpretation. Although it may indicate
acute enteric fever infection, it could also represent chronic car-
riage, with the acute infection syndrome caused by a different
organism.
Isolates of Salmonella serovar Typhi and Salmonella serovar
Paratyphi A should be handled with care in the laboratory, as they
have been a common cause of laboratory-acquired infection.
Many jurisdictions recommend handling these pathogens under
biosafety level 3 conditions. Adequate disposal of specimens and
cultures by autoclaving is essential.
Serologic Assays
Antibody detection. The Widal test measures agglutinating anti-
bodies against LPS (O) and flagellar (H) antigens of Salmonella
serovar Typhi in the sera of individuals with suspected enteric
fever (237). Although usually discouraged due to inaccuracy, it is
simple and inexpensive to perform and is still widely used in some
countries (238). The performance of the method has been ham-
pered by a lack of standardization of reagents and inappropriate
result interpretation (239, 240). The Widal test ideally requires
both acute- and convalescent-phase serum samples taken approx-
imately 10 days apart; a positive result is determined by a 4-fold
increase in antibody titer. However, antibody titers in infected
patients often rise before the clinical onset, making it difficult to
demonstrate the required 4-fold rise between initial and subse-
quent samples (237, 241). In practice, the result from a single,
acute-phase serum sample is often used, but false-negative and
false-positive results are common. Knowledge of the background
levels of antibodies in the local population may aid interpretation
of the Widal test, and performance is best among patients with a
high prior probability of enteric fever (242, 243). For example, in
a study from Vietnam using Widal test data from patients with
typhoid fever and both febrile and healthy control participants, it
was found that a cutoff titer of200 for O agglutination or100
for H agglutination would correctly diagnose 74% of blood cul-
ture-positive patients. However, 14% of positive results were clas-
sified as false positive and 10% of negative results as false negative
(243).
Enzyme-linked immunosorbent assays (ELISAs) have been
used to study the normal antibody response during enteric fever to
LPS, flagella, Vi capsular polysaccharide, or outer membrane pro-
tein antigens (244–251). Although ELISAs measuring anti-LPS
antibodies and antiflagellum antigens are more sensitive than the
Widal “O” and “H” antigen-based test, the results are still limited
by lack of specificity. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) immunoblotting has also been used
to detect serum antibodies against LPS and flagellar antigens of
Salmonella serovar Typhi and Salmonella serovars Paratyphi A,
Paratyphi B, and Paratyphi C (252).
Rapid serologic tests. There are a number of commercially
available point-of-care rapid serologic tests for enteric fever. Their
characteristics are summarized in Table 4 and in a recent review
(253). The tests currently available have different methods and
formats. Most have been developed for use with blood, including
venous whole-blood, serum, or capillary samples, and detect an-
tibody directed against Salmonella antigens. The antibody class
detected is usually IgM, which is suggestive of a current or recent
infection. Some rapid tests detect IgG, which may indicate a cur-
rent infection or previous exposure.
Typhidot (Malaysian Biodiagnostic Research Sdn Bhd, Kuala
Lumpur, Malaysia) detects specific IgM and IgG antibodies
against a 50-kDa Salmonella serovar Typhi outer membrane pro-
tein (OMP) in an immunodot test format. Typhidot-M is a mod-
ified version of Typhidot but detects IgM to the sameOMP and as
a more specific marker of current acute infection (254–260). Re-
ported sensitivities vary between 67 and 98% for Typhidot and
between 47 and 98% for Typhidot-M, with specificities of 73 to
100% for Typhidot and 65 to 93% for Typhidot-M. The Typhi-
Rapid IgM and TyphiRapid IgG IgM (Combo) are similar ver-
sions of the test but in an ICT cassette format (261, 262). Tubex TF
(IDL Biotech, Sollentuna, Sweden) detects antibody against Sal-
monella serovar Typhi LPS with an inhibition assay format and
visual result readout (249, 256–260, 263). Reported sensitivities
for Tubex TF vary between 56 to 100%, with specificities of 58 to
100%. Amodification for paratyphoid diagnosis has recently been
developed (264). TheRoyal Tropical Institute (KIT),Netherlands,
has developed a test detecting IgM against LPS using a dipstick,
latex agglutination, and,most recently, a lateral-flow format (Life-
Assay, CapeTown, SouthAfrica) (249, 265, 266). Studies using the
lateral-flow test report sensitivities of 60% and specificities of
98%. Other rapid test kits available include the following: an
ELISA and dipstick (Multi-Test Dip-S-Ticks) from PanBio (Pan-
Bio Indx, Inc., Baltimore, MD) detecting anti-LPS IgG and IgM;
Mega-Salmonella (Mega Diagnostics, Los Angeles, CA), which is
an ELISA detecting IgG and IgM antibodies against an undefined
Salmonella serovar Typhi antigen; the SD Bioline Typhoid rapid
test (StandardDiagnostics, Kyonggi-do, SouthKorea), which uses
an immunochromatographic method to detect IgG and IgM an-
tibodies against another undefined Salmonella serovar Typhi an-
tigen; and a dipstick test named Enterocheck-WB (Zephyr Bio-
medicals, Goa, India) that detects anti-LPS IgM antibodies (257,
259, 267, 268). A number of other tests are commercially available
but have not been evaluated in published studies.
Although rapid serologic tests may represent some improve-
ment over the Widal test, currently available results suggest that
they still lack sensitivity and also specificity because of the back-
ground antibody levels in the general population (269) and the
cross-reactive nature of the selected antigens. Accurate evaluation
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of the tests is also hampered by the absence of a satisfactory refer-
ence standard. A recent systematic review of studies of two widely
used tests, Tubex TF and Typhidot, concluded that the perfor-
mance characteristics did not justify their use (270).
Molecular Assays
Nucleic acid amplification tests, including conventional PCR and
real-time PCR, have been developed for the detection of both
Salmonella serovars Typhi and Paratyphi A,mainly in blood (271–
288). Nucleic acid amplification methods have the potential to
amplify small numbers of organisms and nonculturable bacteria,
as well as dead organisms. Targets for Salmonella serovar Typhi
PCR-based assays have included theHdflagellin gene fliC-d (271),
the Vi capsular gene viaB (272), the tyvelose epimerase gene (tyv)
(previously rfbE), the paratose synthase gene (prt) (previously
rfbS), groEL (273), the 16sRNA gene (274), hilA (a regulatory gene
in Salmonella pathogenicity island 1 [SPI-1]) (275), the gene en-
coding the 50-kDa outer membrane protein ST50 (276), and the
hypothetical protein gene ratA (277). Nested primers have been
used in some studies to improve sensitivity, although thismay lead
to unspecific amplification and contamination.
The sensitivity of PCR without enrichment in blood-culture
positive cases has exceeded 90% in some studies (271, 273, 278–
286), although other studies have reported much lower sensitivi-
tiesmore consistentwith the number of bacteria in the blood (266,
272, 287). Bone marrow aspirates were examined in one study,
with 100% sensitivity (287), and positive results have also been
found in urine samples (288). The specificity among patients with
other conditions has usually been 100%. Several studies have re-
ported patients with clinically suspected typhoid who are PCR
positive and blood culture negative (266, 272). The absence of a
perfect reference standard makes interpretation of these results
challenging.
Other Diagnostic Tests
Assays to detect bacterial antigens such as Vi, O9, and Hd in urine
have been used as diagnostic methods for enteric fever but with
variable results (235, 289–293). The greatest level of sensitivitywas
found with the Vi antigen, whereas the O9 and Hd antigens were
less sensitive. The sensitivity for Vi increased when multiple sam-
ples were examined, but the specificity was less satisfactory, par-
ticularly in patients with brucellosis. In studies of patients from
Indonesia on detection of O9 antigen in urine using an ELISA and
dot blot format, the sensitivity increased from 65% to 95% when
between one and three urine samples were examined (292). In a
further study in Vietnam, the sensitivity was 92% and specificity
72% when three serial urine samples were compared with blood
culture (293). These data indicate the intermittent nature of anti-
gen excretion in the urine during an infection. Studies detectingVi
and other antigens in serum have also been performed, with vari-
able results (294–299).
New Diagnostic Approaches
There is a considerable research effort aimed at developing new
diagnostics for enteric fever (203). Increasing knowledge of the
Salmonella serovar Typhi and Salmonella serovar Paratyphi A ge-
nomes should lead to better targets for nucleic acid amplification
tests (300–303). Methods to remove potential inhibitory human
DNA from the samplemay improve sensitivity (304), asmay com-
bining short periods of blood culture broth incubation with PCR
amplification (305). Proteomic and immunoscreening ap-
proaches are being used to seek antibodies and antigens that have
a higher level of specificity than those used currently used
(306–311). Analysis of bacterial gene expression in typhoid and
paratyphoid may also lead to new diagnostic tests (312–314).
TABLE 4 Characteristics of selected serologic tests used for the diagnosis of infection with Salmonella Typhi and Salmonella Paratyphi A
Test Test methodology Reported characteristicsb Reference(s)
Enterocheck-WB Dipstick detecting anti-LPS IgM antibodies Sensitivity, 89%; specificity, 97% 268
LifeAssay Test-it Detects IgM antibodies against Salmonella Typhi LPS in an ICT LFA
cassette format
Sensitivity, 59%; specificity, 98% 265, 266
Mega Salmonella ELISA detecting IgG and IgM antibodies against an undefined
Salmonella Typhi antigen
Sensitivity, 91%; specificity, 49% 257
Multi-Test-Dip-S-Ticks Dipstick detecting anti-LPS IgG and IgM Sensitivity, 89%; specificity, 53% 259
PanBio ELISA detecting anti-LPS IgG and IgM Sensitivity, 78%; specificity, 80% 267
SD Bioline ICT LFA cassette detecting IgG and IgM antibodies against an
undefined Salmonella Typhi antigen
Sensitivity, 69%; specificity, 79% 257
Tubex TF Detects antibody against Salmonella Typhi LPS with an inhibition
assay format and a visual result readout
Sensitivity, 56–100%; specificity,
58–100%
249, 255–260,
263, 270
Typhidot Measures IgM and IgG antibodies against a 50-kDa outer membrane
protein of Salmonella Typhi in an immunodot test format
Sensitivity, 67–98%; specificity,
58–100%
254, 255, 257,
259, 260, 269
Typhidot M Measures IgM antibodies, after removal of IgG antibodies, against a
50-kDa outer membrane protein of Salmonella Typhi in a dot blot
format
Sensitivity, 47–98%; specificity,
65–93%
254, 255, 258
TyphiRapid IgM and
IgG IgM (Combo)
Measures IgM antibodies, after removal of IgG antibodies, against a
50-kDa outer membrane protein of Salmonella Typhi in an ICT
LFAa cassette format
Sensitivity, 89–100%; specificity,
85–89%
261, 262
Widal test Measures agglutinating antibodies against O and H antigens of
Salmonella Typhi and Salmonella Paratyphi A; uses a tube or slide
format
Very variable sensitivity and specificity;
lack of standardized reagents
237–240, 242, 243
a ICT, immunochromatographic test; LFA, lateral-flow assay.
b This column shows the range of sensitivity and specificity values from different studies with a range of sample sizes and methodologies. Where there is only one study, that value is
given. For a systematic review of the studies examining Tubex TF and Typhidot, see reference 270.
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Other Laboratory Findings In Enteric Fever
Most patients with enteric fever have a total white cell count
within the normal range. Leukocytosis may suggest an intestinal
perforation or another diagnosis. Eosinopenia is a common al-
though nonspecific finding (51). A normochromic anemia, mild
thrombocytopenia, and an increased erythrocyte sedimentation
rate are common. There may be laboratory markers of a mild
disseminated intravascular coagulation, although this rarely ap-
pears to be of clinical relevance (208). Elevation of alanine
transaminases and aspartate transaminase to two to three times
the normal level is a frequent accompaniment (52).
ANTIMICROBIAL RESISTANCE
Development of Antimicrobial Resistance among Typhoidal
Salmonella Strains
Figure 3 summarizes the current global distribution of antimicro-
bial drug resistance in Salmonella Typhi. Prior to the mid-1970s,
chloramphenicol was the mainstay of treatment of enteric fever
(315–317). However, reports on chloramphenicol-resistant iso-
lates began to appear before 1970 (318, 319). In 1972, the first
epidemic caused by a chloramphenicol-resistant strain was re-
ported from Mexico (320). Soon thereafter, outbreaks involving
chloramphenicol-resistant Salmonella serovar Typhi were re-
ported from several different areas, including India (321), Viet-
nam (322, 323), SouthKorea (324), andBangladesh (325). A com-
mon feature of the outbreak strains was that the chloramphenicol
resistance determinant was located on a self-transmissible plas-
mid of the HI1 incompatibility type (IncHI) (325, 326). In addi-
tion to chloramphenicol resistance, these plasmids often carried
genes conferring resistance to other drugs, such as streptomycin,
sulfonamides, and tetracyclines (325, 326).
The development of chloramphenicol resistance led to increased
use of two other first-line drugs, ampicillin and trimethoprim-sulfa-
methoxazole. Trimethoprim-sulfamethoxazole remained an effec-
tive drug until 1975, when resistance was reported from France
(327). By the late 1980s, multiple-drug resistance (MDR), defined
as resistance to ampicillin, chloramphenicol, and trimethoprim-
sulfamethoxazole, was reported from multiple countries (328–
330). Cases of enteric fever caused by MDR Salmonella serovars
Typhi and Paratyphi A continued to emerge in the 1990s and early
2000s (331–336). Among Salmonella Typhi isolates collected in
Vietnam in 1993 to 1996, 80% were reported to be MDR (82). A
similar prevalence was reported from Africa among isolates col-
lected in Kenya and Nigeria in 2004 to 2006 (70 and 61% MDR,
respectively) (338, 339). In Europe, a large retrospective study
looking at 692 Salmonella serovar Typhi isolates collected in 2002
to 2003 documented a 22% prevalence of the MDR phenotype
(337). A study inDelhi, India, found thatMDR Salmonella serovar
Typhi increased from 34% in 1999 to 66% in 2005 (340). Today,
MDR Salmonella Typhi is considered endemic in many develop-
ing countries, especially in areas of South and Southeast Asia.
In response to the development and spread of MDR Salmonella
serovar Typhi, the use of fluoroquinolone antimicrobials such as
ciprofloxacin was recommended as an alternative for the treat-
ment of typhoid fever (325, 342). However, resistance among Sal-
monella serovar Typhi isolates developed within a short period,
with the first case being reported in 1992 from the United King-
dom (343). This was soon followed by similar reports from other
countries, such as South Korea, India, and Vietnam (344, 345).
The first epidemic involving a fluoroquinolone-resistant Salmo-
nella serovar Typhi isolate occurred in Tajikistan in 1997 (346).
The same year, 60% of Salmonella serovar Typhi isolates in India
displayed aMIC of2g/ml to ciprofloxacin (345). Similarly, an
increase in Salmonella serovar Paratyphi A isolates with cipro-
floxacinMICs of2g/ml was reported fromNewDelhi in 2000
(347), and a ciprofloxacin-resistant isolate with a MIC of 128
g/ml was isolated in Japan in 2002 (348). By 2008, there were
reports of ciprofloxacin-resistant Salmonella serovar Typhi from
multiple centers in India (349–352). In 2010, a tertiary hospital in
Chandigarh, India, reported that 13.6% of isolates were cipro-
floxacin resistant (353). In 2013, a tertiary care center in New
Delhi reported that 37.9% of 344 typhoidal Salmonella isolates
were ciprofloxacin resistant (354). In association with increased
use of ciprofloxacin, several areas have observed a decline in chlor-
FIG 3 Worldwide distribution of antimicrobial drug resistance in Salmonella enterica serovar Typhi. (Reprinted from reference 604 with permission from
Elsevier.)
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amphenicol resistance and MDR prevalence among both Salmo-
nella serovar Typhi and Paratyphi A isolates (355). Although this
is an encouraging trend, the reintroduction of chloramphenicol as
first-line treatment would likely result in reemergence of MDR
isolates.
Decreased susceptibility to fluoroquinolones, often associated
with nalidixic acid resistance, has also been observed in countries
where these infections are not endemic, where the majority of
cases are associated with international travel. In 1999, decreased
susceptibility to fluoroquinolones was detected in 23% of all Sal-
monella serovar Typhi isolates in the United Kingdom (356). In
the United States, the proportion of nalidixic acid-resistant iso-
lates increased from 19% in 1999 to 42% in 2004 and in Canada,
nalidixic acid resistant isolates rose from 40% to 80% between
2000 and 2006 (357, 358). A similar trend was observed in the
United Kingdom, where the proportion of Salmonella serovar Ty-
phi isolates with decreased susceptibility to ciprofloxacin in-
creased from 35% in 2001 to 70% in 2006 (359).
In areas with a high prevalence of both MDR and fluoroquin-
olone resistance, azithromycin, an azalide antimicrobial that has
demonstrated good efficacy against uncomplicated enteric fever
in multiple clinical trials (360), and extended-spectrum cephalo-
sporins (e.g., ceftriaxone) tend to be used for the treatment of
enteric fever. However, Salmonella serovar Typhi isolates display-
ing resistance to extended-spectrum cephalosporins have been
described. For example, extended-spectrum -lactamase (ESBL)
enzymes of the SHV-12 and CTX-M types and an AmpC -lacta-
mase of the ACC-1 type have been reported among Salmonella
serovar Typhi isolates from Germany, the Philippines, Bangla-
desh, and India (361–364). In 2013, anMDR isolate of Salmonella
serovar Paratyphi A harboring a CTX-M-15 -lactamase was de-
tected in a Japanese traveler returning from India (605). Similarly,
there have been sporadic reports of azithromycin resistance. A
recent study from India reported increasing prevalence of azithro-
mycin resistance among typhoidal Salmonella isolates; among 344
isolates collected in 2010 to 2012, 7.3% were resistant to azithro-
mycin using disk diffusion interpretive criteria suggested by the
British Society for Antimicrobial Chemotherapy (BSAC) (354).
Importantly, an increasing prevalence of azithromycin resistance
was observed for both Salmonella serovars Typhi and Paratyphi A
over the 2-year study period (354).
Development of Antimicrobial Resistance among
Nontyphoidal Salmonella Strains
As for typhoidal Salmonella, an increasing prevalence of antimi-
crobial resistance has been observed in nontyphoidal Salmonella
over recent decades. An important trend has been the develop-
ment ofMDRamong isolates of Salmonella serovar Typhimurium
but also other serovars. The MDR phenotype in Salmonella sero-
var Typhimuriumbegan to appear in the early 1980s in theUnited
Kingdom, where it was closely associated with a specific phage
type called definitive type 104 (DT104) (365). These isolates dis-
played resistance to five antimicrobial agents—ampicillin, chlor-
amphenicol, streptomycin, sulfonamides, and tetracycline—a re-
sistance phenotype commonly referred to as R-type ACSSuT. By
the 1990s, this phenotype had been reported from several other
countries in Europe as well as the United States, Canada, Israel,
Turkey, and Japan (366, 367). However, Salmonella serovar Ty-
phimurium with R-type ACSSuT has been declining in many
countries since that time. In the United States, this phenotype
accounted for 35% of all Salmonella serovar Typhimurium iso-
lates submitted to the U.S. National Antimicrobial Monitoring
System (NARMS) in 1997.However, between 1998 and 2005 there
was a steady decline from 32% to 22%, and in 2011 20% of all
Salmonella serovar Typhimurium isolates collected from humans
displayed this phenotype (368, 369).
Another important resistance trend among nontyphoidal Sal-
monella isolates has been the development of resistance to quino-
lones (i.e., nalidixic acid) and fluoroquinolones such as cipro-
floxacin. Although nalidixic acid is not used for treatment,
development of resistance to this drug is of clinical importance
since it may be associated with reduced clinical effectiveness of
fluoroquinolone treatments (370, 371). Reports of quinolone re-
sistance among nontyphoidal Salmonella strains followed soon
after the introduction of fluoroquinolones. In Denmark, quino-
lone resistance in Salmonella serovar Enteritidis increased from
0.8% in 1995 to 8.5% in 2000. In the early 2000s, a large European
surveillance study including 27,000 isolates reported low-level
fluoroquinolone resistance in 13% of Salmonella serovar Typhi-
murium, 8% of Salmonella serovar Enteritidis, 53% of Salmonella
serovar Virchow, and 57% of Salmonella serovar Hadar (372) iso-
lates. In Southeast Asia, several studies have documented the
emergence of quinolone- and fluoroquinolone-resistant Salmo-
nella strains. In 2009, a high prevalence of reduced susceptibility to
ciprofloxacin was reported among Salmonella strains from the
Philippines (15%), Singapore (25%), and Thailand (46.2%)
(373). In 2011, 31% of isolates were fully resistant to ciprofloxacin
in a study from Thailand (374). The prevalence of fluoroquin-
olone-resistant isolates in high-income countries has been found
to be lower (107). Among 2,344 nontyphoidal Salmonella isolates
collected in the United States in 2011, 0.2% were ciprofloxacin
resistant (369).
The development of nontyphoidal Salmonella isolates resistant
to extended-spectrum cephalosporins, such as ceftriaxone, repre-
sents another substantial public health concern. These drugs are
important for treating invasive Salmonella infections, especially
among children, among whom fluoroquinolones may be avoided.
Resistance to extended-spectrum cephalosporins has been recog-
nized in nontyphoidal Salmonella since themid-1980s and is com-
monlymediated through-lactamases of the ESBLorAmpC type.
Some of the earliest reports on cephalosporin-resistant isolates of
nontyphoidal Salmonella originated in North Africa. During 1984
and 1990, cephalosporin-resistant strains were frequently isolated
in pediatric units of Tunisian hospitals (375, 376). In Southeast
Asia, cephalosporin resistance has been reported from Singapore,
the Philippines, and Thailand (373, 377). In Thailand, isolates
harboring enzymes of the CMY and CTX-M types have been de-
scribed (378, 379). Importantly, some of the cephalosporin-resis-
tant nontyphoidal Salmonella isolates in Thailand also show resis-
tance to fluoroquinolones (379–381). Such infections might
require the use of more expensive drugs such as carbapenems or
tigecycline.
In Europe, cephalosporin-resistant nontyphoidal Salmonella
was first detected in France and Italy in 1989 and 1990, respec-
tively (382, 383). A CTX-M-producing clone of Salmonella sero-
var Typhimurium spread inRussia,Hungary, andGreece between
1996 and 1999, and sporadic cases and outbreaks involving CMY-
producing Salmonella serovar Newport were reported from
France between 2000 and 2005 (375, 384).
In North America, reports on -lactamase-producing isolates
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of nontyphoidal Salmonella started to appear in themid-1990s. In
the United States, a national survey of 4,003 Salmonella isolates
collected in 1995 found 3 (0.1%) ceftriaxone-resistant isolates,
each of which had been acquired outside the United States (385).
Early reports of ceftriaxone-resistant nontyphoidal Salmonella ap-
peared in the mid- to late 1990s (386). The first ESBL-producing
strain detected in Canada was an SHV-producing Salmonella se-
rovar Typhimurium strain identified in 2000 (387). Two years
later, the first CMY-producing Salmonella strain was reported
during a small outbreak of Salmonella serovarNewport in Alberta,
Canada (388). Since then, multiple studies have reported on the
occurrence of CMY and ESBL enzymes among Salmonella isolates
collected from human, animal, and retail meat sources in Canada
and the United States (389–399). Perhaps the most notable trend
in the United States has been the emergence of MDR Salmonella
serovar Newport with an AmpC phenotype (400). These strains
emerged in the early 2000s and harbored plasmids encoding ceph-
alosporin resistance (blaCMY) and the R-type ACSSuT phenotype
(400). According to NARMS, the proportion of Salmonella sero-
var Newport isolates with this phenotype peaked at 25% in 2001
but had declined to 13% by 2005. More recently ceftriaxone-re-
sistant Salmonella serovar Heidelberg has emerged in the United
States (390, 401).
Over recent years, several reports have documented the emer-
gence of extensively drug-resistant isolates of nontyphoidal Sal-
monella. Salmonella serovar Typhimurium isolates resistant to 12
to 15 antimicrobial agents, comprising 6 or 7 CLSI drug classes,
including cephems, have been reported from Malaysia and Viet-
nam (402–404). Similarly, Salmonella isolates resistant to 6 or 7
antimicrobial agents, comprising 3 to 5 CLSI drug classes, have
been detected in Thailand (374). A recent trend is the develop-
ment of extensively drug-resistant isolates of Salmonella serovar
Kentucky. A ciprofloxacin-resistant strain of Salmonella serovar
Kentucky (ST198-X1) that originally emerged in Egypt and spread
throughout Africa and theMiddle East from2002 to 2008 has now
acquired additional resistance (405). Since 2009, variants display-
ing resistance to extended-spectrum cephalosporins and carbap-
enems have been detected. Nontyphoidal Salmonella isolates dis-
playing carbapenem resistance have been reported from multiple
countries, including China, Columbia, Pakistan, and the United
States. Among these isolates, Klebsiella pneumoniae carbapen-
emase and New Delhi metallo-beta-lactamase-1 enzymes were
most prevalent (406–410). Of concern is that some of these iso-
lates are also resistant to most aminoglycosides, trimethoprim-
sulfamethoxazole, and azithromycin (405).
Molecular Mechanisms of Resistance
Multiple-drug resistance. Among typhoidal Salmonella isolates,
resistance to the traditional first-line antimicrobials ampicillin,
chloramphenicol, and trimethoprim-sulfamethoxazole is com-
monly caused by resistance determinants located on plasmids.
Resistance to ampicillin is often mediated through -lactamases
(e.g., blaPSE and blaTEM), whereas several mechanisms may be as-
sociated with chloramphenicol resistance. Three types of chlor-
amphenicol acetyltransferases (CATs) (types I to III) have been
described in Gram-negative bacteria, but resistance due to the
production of CAT of type I has been encountered most fre-
quently in Enterobacteriaceae (411). Genes involving nonenzy-
matic resistance mechanisms, such as cmlA and floR, have also
been found in Salmonella enterica (411, 412). Both trimethoprim
and sulfamethoxazole are folate pathway inhibitors that prevent
the synthesis of DNA. Resistance to both drugs occurs by acquisi-
tion of genes encoding folate pathway enzymes that do not bind
these compounds. In Salmonella enterica, resistance to trim-
ethoprim is mediated through various dihydrofolate reductase
(dfr) genes, whereas sulfamethoxazole resistance is due to the
presence of sul genes such as sul1 or sul2 (412).
The genes mediating R-type ACSSuT in nontyphoidal Salmo-
nella are commonly clustered together in a chromosomal genetic
element called Salmonella genomic island 1 (SGI-1). This element
was first identified in Salmonella serovar Typhimurium DT104
but has since then been detected inmany other serovars, including
Salmonella serovars Agona, Albany, Cerro, Derby, Dusseldorf,
Emek, Haifa, Infantis, Kentucky, Kiambu, Kingston, Meleagridis,
Newport, Paratyphi B, and Tallahassee (413–415). In the classic
SGI-1, a 14-kb region bracketed by two integron structures within
this chromosomal element contains the antimicrobial resistance
genes contributing to its ACSSuT properties: blaPSE-1 conferring
resistance to ampicillin, floR to chloramphenicol and florfenicol,
aadA2 to streptomycin, sul1 to sulfonamides, and tetG to tetracy-
cline (416).
Fluoroquinolone resistance. Fluoroquinolones target the two
enzymes DNA gyrase and topoisomerase IV, whose subunits are
encoded by the gyrA and gyrB and the parC and parE genes (417).
Mutations in the quinolone resistance-determining regions
(QRDRs) of these genes may confer reduced susceptibility or re-
sistance to fluoroquinolones, depending on the number of muta-
tions acquired (417, 418). A single point mutation in the gyrA
gene, typically Ser-83 to Phe, Ser-83 to Tyr, Asp-87 to Asn, or
Asp-87 to Gly, will confer resistance to the quinolone nalidixic
acid and decreased susceptibility to ciprofloxacin. Two or more
mutations in the gyrA gene or other topoisomerase genes are re-
quired to confer full clinical resistance to ciprofloxacin (MIC,1
g/ml) (418–421).
In addition to the chromosomally encoded mechanisms, plas-
mid-mediated resistance mechanisms have been described. The
first plasmid-mediated quinolone resistance (PMQR) mecha-
nism, qnrA, was described in the late 1990s, and since then, a
variety of other plasmid-mediatedmechanisms have been discov-
ered in Enterobacteriaceae, including different qnr variants,
aac(6=)-Ib-cr, qepA, and oqxAB (422, 423). Among nontyphoidal
Salmonella strains, a number of qnr variants and the aac(6=)-Ib-cr
mechanism have been detected (424). Reports on PMQRmecha-
nisms among typhoidal Salmonella isolates are rare but include a
qnrB2-producing isolate detected in Germany and three qnrS1-
producing isolates detected in the United States (364, 425). The
plasmid-mediatedmechanisms typically confer decreased suscep-
tibility to ciprofloxacin in theMIC range of 0.125 to 1.0g/ml and
a modest increase in susceptibility to nalidixic acid in the MIC
range of 8 to 32 g/ml (422, 426, 427).
Cephalosporin resistance.Cephalosporins belong to the group
of -lactam antimicrobials and disrupt the bacterial cell wall syn-
thesis by targeting penicillin binding proteins (PBPs) and the
cross-linking of the peptidoglycan (428). Resistance to cephalo-
sporins, including extended-spectrum cephalosporins such as
ceftriaxone, is commonlymediated through-lactamases that in-
activate the drug by cleaving the -lactam ring. The -lactamases
mediating resistance to extended-spectrum cephalosporins can be
divided into three groups: extended-spectrum -lactamases
(ESBLs), carbapenemases, and AmpC-type -lactamases (429,
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430). Among the AmpC plasmid-mediated -lactamases, cepha-
mycinases (CMY), encoded by blaCMY genes, are the predominant
cause of cephalosporin resistance in nontyphoidal Salmonella.
The genes encoding the -lactamase enzymes are commonly lo-
cated on mobile genetic elements such as plasmids, transposons,
and integrons. Consequently, resistance may spread horizontally
between isolates, clones, and serovars.
Macrolide resistance. Macrolides inhibit protein synthesis by
binding to the 50S subunit of the bacterial ribosome. Resistance
mechanisms have been detected in Salmonella enterica isolates
with elevated azithromycin MICs, here defined as MICs of 16
g/ml. Among nontyphoidal Salmonella isolates, a macrolide-2=-
phosphotransferase encoded by the mphA gene has been de-
scribed (405, 431). The first case of azithromycin treatment failure
in a patient with invasive Salmonella infection was reported in
2010 (432). This infection was due to a Salmonella serovar Para-
typhi A isolate displaying an azithromycin MIC of 256 g/ml
(432).
ANTIMICROBIAL MANAGEMENT
The aims of management of invasive Salmonella infections are to
resolve clinical symptoms by eliminating the infection with anti-
microbials, to provide supportive treatment with fluids and nutri-
tion, and tomonitor for the development of complications. Effec-
tive antimicrobial therapy reduces mortality and complications
and shortens the illness. In enteric fever, antimicrobial treatment
may eradicate fecal carriage and reduce onward transmission. In
areas of endemicity, antimicrobial treatment for typhoid fever is
often started empirically based on the syndrome of fever for 3 to 4
days ormore, constitutional symptoms (e.g., malaise and fatigue),
symptoms or signs in the gastrointestinal system, a negative ma-
laria smear, and no other clear source of infection. Antimicrobial
agents are not recommended for treatment of nonsevere, nonty-
phoidal Salmonella diarrhea in healthy adults or children, but
they are recommended for people with evidence of sepsis or
extraintestinal infection or for specific populations at risk for
bacteremia and disseminated disease.
Enteric fever is an intracellular infection involving the reticu-
loendothelial system, particularly bone marrow, liver, and spleen
(52). Invasive nontyphoidal Salmonella has also been shown to
establish an intracellular niche in the blood and bone marrow
(162). Therefore, effective treatment depends on the ability of
antimicrobials to penetrate intracellular sites of infection in the
reticuloendothelial system and gallbladder. Some antimicrobials,
including gentamicin and first- and second-generation cephalo-
sporins such as cefuroxime, appear to be effective in vitro but are
ineffective in vivo and should not be used in enteric fever (433).
Traditional First-Line Antimicrobials
Chloramphenicol was the first antimicrobial found to be effective
in enteric fever and for many years was the standard treatment
(315). Treatment with chloramphenicol led to symptom resolu-
tion within 4 to 6 days and transformed a prolonged, debilitating,
and potentially fatal disease into a treatable condition with a low
case fatality ratio. A physician using chloramphenicol to treat ty-
phoid fever for the first time commented: “. . .the clinical im-
provement and complete transformation in a few days can only be
appreciated by clinicians who have had previous experience of
typhoid fever and have known their ownhelplessness in the past to
affect its protracted course. . . its great value in saving life and
curtailing morbidity in this disease is incontestable” (434). Oral
chloramphenicol treatment results in serum concentrations be-
tween 5 and 20 g/ml above the usual wild-type MIC (435). The
succinate ester prodrug is used for intravenous or intramuscular
administration and gives lower serum levels than the oral form
(436, 437). Chloramphenicol has been shown to be clinically ef-
fective in a number of studies (341, 438–447). Disadvantages of
chloramphenicol are its four-times-daily administration and the
need to give it for at least 2 weeks to reduce the 10 to 15% risk of
relapse. Dose-related and reversible bone marrow depression and
irreversible bone marrow aplasia that is rare, unpredictable, and
often fatal may occur (448). Amoxicillin and trimethoprim-sulfa-
methoxazole were shown to have efficacy generally comparable to
that of chloramphenicol with less risk of toxicity, although they
also needed to be given for at least 2 weeks to avoid relapse (439,
449–456). The experience with mecillinam was less convincing
(456–458). Chloramphenicol, amoxicillin, and trimethoprim-
sulfamethoxazole were widely available and affordable in areas of
endemicity and remained the standard of care formany years. The
emergence and spread of MDR strains of Salmonella serovars Ty-
phi and Paratyphi A led to the evaluation of new antimicrobials.
The extended-spectrum cephalosporins, fluoroquinolones, and
azithromycin were established as effective alternatives.
Fluoroquinolones
The fluoroquinolones, in particular ciprofloxacin and ofloxacin
but also including fleroxacin and pefloxacin, were evaluated for
enteric fever treatment as the MDR strains emerged. Peak plasma
levels of ciprofloxacin and ofloxacin after oral administration
were initially well above the prevailing MICs of infecting strains
(481–483). The drugs were concentrated intracellularly at the site
of infection (484, 485) and were rapidly bactericidal in vitro (481,
486). When given for duration of 7 to 14 days, fluoroquinolones
were often 100% effective with very low levels of relapse (329, 342,
443, 470, 487–505). The clinical response was rapid, with fever
resolution within 3 to 5 days. A number of studies were con-
ducted, predominantly in Vietnam, with a shorter course of treat-
ment of 5 days (506, 507) or 2 or 3 days (507–510) in uncompli-
cated disease with broadly similar results. Fleroxacin and
pefloxacin were equally effective, although norfloxacin is not rec-
ommended because of low tissue concentrations. As these fluoro-
quinolones could conveniently be given orally and local generi-
cally produced drugs were relatively affordable, they became
widely used for treating suspected and confirmed cases of enteric
fever.
For invasive nontyphoidal Salmonella there is only very limited
historical experience of the use of chloramphenicol compared to
ciprofloxacin. Ciprofloxacin was introduced following the emer-
gence of resistance to chloramphenicol (114) in treatment of in-
vasive nontyphoidal Salmonella in Africa. The reported recur-
rence ratio after treatment with chloramphenicol was 43% (154),
compared to 30% following treatment with ciprofloxacin (162).
This difference might be attributable to improved intracellular
penetration of the fluoroquinolone. The case fatality ratio also fell
gradually over the reported period, but this could be attributable
to multiple effects other than the change in antimicrobial use
(114).
Over time, physicians in areas of endemicity and those treating
returning travelers began to report cases of fluoroquinolone fail-
ure when treating enteric fever despite the laboratory reporting a
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susceptible isolate (343, 419, 511–519). It became clear that a sub-
set of strains of Salmonella serovars Typhi and Paratyphi A had
emerged that were less susceptible to the fluoroquinolones. They
showed decreased susceptibility to ciprofloxacin (MICs of 0.125
to 0.5g/ml, compared with the wild-typeMIC of0.03g/ml),
and the decreased susceptibility is most commonly mediated by
pointmutations in genes encodingDNAgyrase, the target enzyme
for the drug (486, 513, 514, 520–522). Isolates that have this de-
creased-susceptibility phenotype were not defined as resistant by
the existing ciprofloxacin interpretive criteria for disk diffusion
but were usually found to be nalidixic acid resistant. Nalidixic acid
resistance has proved to be a useful, although not a completely
accurate, laboratorymarker of decreased fluoroquinolone suscep-
tibility (337). The accumulating evidence that these strains are
associated with an impaired response to ciprofloxacin and ofloxa-
cin has led to a recent revision of the Clinical and Laboratory
Standards Institute (CLSI) breakpoint guidelines such that they
are now classified as intermediate (523, 524). Ciprofloxacin-inter-
mediate strains have become common in Asia, sometime causing
large outbreaks, with reports also in sub-Saharan Africa, and
South America (486, 525–529). Studies with whole-genome se-
quencing of global Salmonella serovar Typhi collections have
shown that a particular haplotype, H58, is more likely to be MDR
and to have intermediate susceptibility to ciprofloxacin (530,
531). This haplotype has become dominant in many regions and
may have a competitive advantage compared with other haplo-
types (532–536).
Infection with Salmonella enterica isolates with intermediate
susceptibility to ciprofloxacin may respond to higher doses or
longer durations of treatment with ciprofloxacin or ofloxacin;
failure does not occur in all cases (537). However, even if fluoro-
quinolone treatment of such infections is successful, higher levels
of fecal shedding posttreatment may occur, driving further trans-
mission of strains (520).Where possible, fluoroquinolones should
be avoided in patients infected with strains with intermediate sus-
ceptibility to fluoroquinolones. Alternatives include extended-
spectrum cephalosporins (e.g., ceftriaxone) and, in nonsevere
cases, azithromycin or the traditional first-line antimicrobials, if
susceptible. If fluoroquinolones are the only available option, for
example, in outpatient management, they should be used at the
maximumdose, such as 20mg/kg/day of ciprofloxacin, for at least
7 days.
The later-generation fluoroquinolone gatifloxacin has been
found to be an effective alternative for Salmonella infections with
isolates with intermediate ciprofloxacin susceptibility. A single
daily dose of 10 mg/kg for 7 days has achieved cure in more than
90% of patients and short fever clearance times (341, 480, 537,
538).Gatifloxacin targets bothDNAgyrase and topoisomerase IV.
Therefore, gatifloxacin is less inhibited by the commonmutations
of the gyrA gene of Salmonella serovar Typhi than are ciprofloxa-
cin and ofloxacin (486). Fully fluoroquinolone-resistant Salmo-
nella isolates with a ciprofloxacinMICof1g/ml are unlikely to
respond to any of the fluoroquinolones. Such isolates are increas-
ing in South Asia and are sporadically reported from other coun-
tries (350–352, 539–543).
There are some patient safety concerns with the fluoroquinolo-
nes. A cautionwith children is the potential for damage to growing
weight-bearing joints and cartilage, based on studies in immature
animals. The available evidence in humans suggests that if used in
short courses the risk of an effect on growth and joint develop-
ment is low and that musculo-skeletal side effects are reversible
(544–551). In most countries the use of fluoroquinolones in chil-
dren is relatively contraindicated except for use in multidrug re-
sistant infections where there are no suitable alternative. The fluo-
roquinolones do carry a risk of tendon damage in patients over 60
years of age, those on concomitant corticosteroids, or those with a
history of tendon disorders. Dysglycemia among the elderly and
those with diabetes has been reported with gatifloxacin, leading to
the withdrawal of the drug from the American and other markets
(552). Carefulmonitoring of glucose levels in patients recruited to
typhoid studies inNepal have not shown adverse effects, andmost
typhoid fever cases in areas of endemicity occur in children and
young adults rather than the elderly (341). While it is uncommon
for patients with typhoid fever to have diabetes in areas of ende-
micity, diabetes is an emerging problem among adults in South
Asia. Gatifloxacin should be avoided in patients over 50 years of
age and in those with diabetes or renal failure.
Extended-Spectrum Cephalosporins
Ceftriaxone has been the principal cephalosporin evaluated in
clinical trials of typhoid fever, although cefotaxime and cefopera-
zone have also proved effective in a few studies (459, 460). Peak
drug levels of ceftriaxone of140g/ml and trough levels of22
g/ml provide unbound concentrations well above a typical MIC
of 0.03 to 0.06 g/ml (461, 462). Ceftriaxone is generally safe to
use, including in children, is slowly bactericidal against Salmonella
serovar Typhi in vitro, and is able to penetrate and kill intracellular
bacteria (463, 464). Ceftriaxone has been used to treat typhoid in
durations of 14 days (465–467), 7 days (342, 468–470), 5 days
(440, 471–473), and 3 days (442, 474, 475). The proportion of
patients cured has varied from 70% to more than 90%. The reso-
lution of symptoms is invariably slow, often with the fever clear-
ance times of 6 to 8 days. Relapse may occur in more than 10% of
patients in some studies, particularly when the duration of treat-
ment is 7 days or less. The optimum duration of treatment is
unclear. While the cost and inconvenience of parenteral adminis-
tration of ceftriaxone are disadvantages, once-daily administra-
tion makes this easier. Oral extended-spectrum cephalosporins
such as cefixime have also been studied. Although early results
were promising (465, 472, 476–478), in two later studies the treat-
ment response was slow and clinical failures and relapses were
seen (479, 480).
Azithromycin
Azithromycin is increasingly being used for empiric treatment of
uncomplicated enteric fever, especially in areas where MDR and
fluoroquinolone-resistant infections are prevalent (444, 469, 501,
511, 516). TheMICs of strains are usually in the range of 0.25 to 16
g/ml (553–556). Serum levels after oral administration are 0.04
to 0.4 g/ml (557). Azithromycin shows excellent penetration
into most tissues and achieves intracellular concentrations inside
macrophages and neutrophils that are 10 to 100 times greater than
serumconcentrations, with slow release from this intracellular site
(558, 559). The drug has a long half-life of 2 to 3 days, allowing
once-daily administration, and is safe to use in children. The im-
munomodulatory effects of azithromycin may also be important
by reversing the immunoparalysis seen in typhoid (28, 29, 560).
Although some initial clinical studies were disappointing (561),
subsequent randomized controlled trials have confirmed azithro-
mycin to be equivalent or superior to chloramphenicol, fluoro-
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quinolones, and extended-spectrum cephalosporins for the man-
agement of uncomplicated typhoid fever and associated with a
prompt resolution of clinical symptoms and low prevalence of
relapse and convalescent fecal carriage (444, 469, 473, 501, 511,
516, 538). Doses have varied between 10 and 20 mg/kg/day for
between 5 and 7 days, and the optimum dose and duration are yet
to be determined. Occasional patients in these studies have dem-
onstrated a slow clearance of bacteremia. Several studies have re-
ported azithromycin MIC distributions for typhoidal and nonty-
phoidal Salmonella strains (501, 511, 562–565). These studies have
led to a suggested epidemiologic MIC cutoff value of16 g/ml
for wild-type strains (566, 567). Clinical interpretive criteria for
disk diffusion and MIC testing have recently been adopted by
CLSI for Salmonella serovar Typhi but not yet for Salmonella se-
rovar Paratyphi A (570). There are sporadic reports of strains with
an azithromycinMICof32g/ml but limited published data on
the clinical response to azithromycin in such infections (432, 562,
563, 568, 569). The newly established CLSI guidelines for azithro-
mycin disk diffusion and MIC interpretive criteria for Salmonella
serovar Typhi were published in CLSI document M100 in 2015
(570).
Carbapenems and Tigecycline
If combinedresistance toallfirst- andsecond-linedrugsdevelops, the
carbapenems (e.g., imipenem, meropenem, and ertapenem), and
tigecycline couldbepotential alternatives (571).Thereare fewreports
describing theuseof thesepotentially expensivedrugs (572). Inmany
areas of South Asia, increasing proportions of Salmonella isolates
have regained susceptibility to the traditional first-line drugs
chloramphenicol, ampicillin, and trimethoprim-sulfamethoxa-
zole. These older drugs could be used again, although the preva-
lence of MDR Salmonella may rise again.
Antimicrobial Combinations
Combinations of fluoroquinolones, cephalosporins, and azithro-
mycin are probably used quite frequently, particularly in patients
who fail to respond promptly (517, 573). The potential advantages
of antimicrobial combinations include a broadening of the spec-
trum of antimicrobial activity, particularly in the face of potential
drug-resistant strains, utilization of any potential synergy between
the drugs, and the potential to reduce the emergence of resistant
strains during the course of treatment. However, there are few
studies of the in vitro interactions between antimicrobials for Sal-
monella isolates (574, 575).
Pregnancy
Ampicillin, amoxicillin, and ceftriaxone are considered safe in
pregnant women with enteric fever (63, 576). Fluoroquinolones
have been occasionally used in pregnant patients infected with
MDR Salmonella isolates (577, 578). Animal studies of azithromy-
cin have not revealed evidence of fetotoxicity, although there are
only limited controlled data in human pregnancy (579). The U.S.
Food and Drug Administration has assigned azithromycin to
pregnancy category B, indicating that it should be given during
pregnancy only when benefit outweighs risk. Azithromycin is ex-
creted into human milk, and the manufacturer recommends that
caution be used when administering azithromycin to nursing
women.
Treatment of Severe Disease
Gastrointestinal bleeding is usually self-limiting, and few patients
require a blood transfusion. In exceptional circumstances, sur-
gery, intra-arterial vasopressin, or colonoscopic interventions
have been used to halt hemorrhage (580–582). The management
of intestinal perforation includes nasogastric suction, administra-
tion of fluids to correct hypotension, and prompt surgery. Surgery
has been demonstrated to lead to improved survival compared
with a conservative approach (73). The survival of patients under-
going surgery for perforation is generally 70 to 75% but reaches
97% in the best series (72–74). In contrast, approximately 30% of
conservatively managed patients survive. Simple closure of perfo-
rations is usually adequate, although procedures to bypass se-
verely affected sections of the ileum are sometimes used. Closure
of perforations should be accompanied by vigorous peritoneal
toilet. Metronidazole or clindamycin should be added to the
therapy of ceftriaxone- or fluoroquinolone-treated patients. Met-
ronidazole and aminoglycosides are recommended for patients
receiving chloramphenicol, ampicillin, or trimethoprim-sulfame-
thoxazole.
Enteric fever patients with altered consciousness and hemody-
namic shock have high case fatality ratios. A study in Jakarta
showed that high doses of dexamethasone substantially reduced
the mortality of such severe cases. The criterion for entry to the
study was marked mental confusion or shock. Among adults
treated with chloramphenicol, dexamethasone at 3 mg/kg infused
intravenously over half an hour, followed by eight doses of 1
mg/kg every 6 h, resulted in a 10% case fatality ratio, compared to
55.6% among controls (76). A study using historical controls
demonstrated a comparable benefit in children (77). Whether
lower doses of glucocorticosteroids would have a similar effect is
unclear. A nonrandomized study in Papua New Guinea using
lower equivalent doses of hydrocortisone failed to replicate this
result (78). It is also unclear whether enteric fever caused by sus-
ceptible typhoidal Salmonella treated with a second-line antimi-
crobial agent such as ceftriaxone or a fluoroquinolone would
achieve a similar result. It has proved difficult to replicate this
study because the number of severe typhoid patients has de-
creased, possibly because of the ready availability of over-the-
counter antimicrobials.
Treatment of Chronic Carriage
Eradication of chronic carriage has been achieved with longer du-
rations of antimicrobial therapy than are required for manage-
ment of acute infection. The choice of antimicrobial depends on
the susceptibility of the strain. Ampicillin or amoxicillin, some-
times combined with probenecid, trimethoprim-sulfamethoxa-
zole, and fluoroquinolones have been used with some success
(583–591). Cholecystectomy can be considered if antimicrobials
fail, but the surgery can carry risks, and there should be additional
indications for operation. The success of surgery for the elimina-
tion of chronic carriage is increased by giving antimicrobials at the
same time (592).
Evidence Needs for Antimicrobial Management
Most physicians base their therapeutic choices on international or
country guidelines, when available, or expert opinion (593–596).
Experience based on routine practice may be unreliable. In low-
resource areas, the diagnosis of invasive Salmonella infection is
usually unconfirmed, and patients treated as outpatients who do
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not improve or subsequently relapse may return to a different
health care facility. Antimicrobials are easily available without
prescription in pharmacies and shops in most developing coun-
tries, and counterfeit or substandard antimicrobials are likely to
be common (597). The detection and management of convales-
cent and chronic carriage are of crucial public health importance,
particularly in the light of widespread drug resistance, but have
received little attention.
The evidence base of randomized controlled trials to guide en-
teric fever treatment is limited and particularly so for invasive
nontyphoidal salmonellosis. Many randomized trials have been
small and underpowered to demonstrate significant differences
between antimicrobial choices. Systematic reviews of the evidence
from existing studies are useful (505, 598). Further well-con-
ducted randomized clinical trials, with detailed microbiology and
accompanying pharmacokinetic and pharmacodynamic analysis,
are essential to define safe and effective regimens for patients.
Such trials are likely to require multicenter designs to be able to
recruit sufficient patients over a reasonable period of time.
The appropriate timing of and early and late outcomes follow-
ing antiretroviral therapy in patients presentingwith invasiveNTS
are almost entirely unknown. This is an area where further study
and practical recommendations would be useful.
CONCLUSIONS
Salmonella enterica infections are common causes of bloodstream
infection in low-resource areas, where they may be difficult to
distinguish from other febrile illnesses andmay be associated with
a high case fatality ratio. Microbiologic culture of blood or bone
marrow remains themainstay of laboratory diagnosis. Antimicro-
bial resistance has emerged in Salmonella enterica, initially to the
traditional first-line drugs chloramphenicol, ampicillin, and trim-
ethoprim-sulfamethoxazole. Decreased fluoroquinolone suscep-
tibility and then fluoroquinolone resistance have developed in
association with chromosomal mutations in the quinolone resis-
tance-determining regions of genes encoding DNA gyrase and
topoisomerase IV and also by plasmid-mediated resistancemech-
anisms. In 2013, CLSI lowered the ciprofloxacin susceptibility
breakpoints to account for accumulating clinical, microbiologic,
and pharmacokinetic-pharmacodynamic data suggesting that re-
vision was needed for contemporary invasive Salmonella infec-
tions (523). Resistance to extended-spectrum cephalosporins has
occurred more often in nontyphoidal than in typhoidal Salmo-
nella strains. Azithromycin is effective for the management of un-
complicated typhoid fever and may serve as an alternative oral
drug in areaswhere fluoroquinolone resistance is common.Newly
established CLSI guidelines for azithromycin disk diffusion and
MIC interpretive criteria for Salmonella serovar Typhi were pub-
lished in CLSI document M100 in 2015 (570).
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